Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)

Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying Chen, Jincheng Wu, Thomas W. Dubensky, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Jason J. Luke

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original version of this article (1), author Thomas W. Dubensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the author contributions and disclosures have been updated as necessary. The authors regret this error.

Original languageEnglish (US)
Pages (from-to)2336
Number of pages1
JournalClinical Cancer Research
Volume29
Issue number12
DOIs
StatePublished - Jun 15 2023

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)'. Together they form a unique fingerprint.

Cite this